TABLE 3.
Sensitivity and specificity with clinical samples
| Clinical status of subjects (n) | TaqMan assay, no. positive (%) | HHV-8 DNA load (copies/ml, range) | Anti-HHV-8, no. positive (%) |
|---|---|---|---|
| HHV-8-related diseases (24) | 20 (83) | <10-560,000 | 23 (96) |
| HIV seropositivea (64) | 2b (3) | <10-138 | 24 (38) |
| Malignant lymphoma and inflammatory diseaseb (16) | 0 | <32c | 0 |
| Healthy blood donors (36) | 0 | <20c | 2 (5) |
a
No ongoing or previous HHV-8-related disorders.
b
Clinical evidence of KS after 8 and 15 months from specimens collection.
c
For negative samples the highest cutoff value is reported.